Novartis announces FortiHFy clinical programme of Entresto
• Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials...
Spark Therapeutics, Pfizer announce data from initial subjects in hemophilia B trial
Subjects received one-time administration of a highly optimized gene therapy at initial low dose without the need for immunosuppression
Therapeutic Factor IX activity...
Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting
• First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna®both in front-line and second-line following Glivec®*• First genomic...
GlaxoSmithKline presents positive data for Anoro Ellipta in COPD patients who remained symptomatic on tiotropium
GlaxoSmithKline and Innoviva, Inc announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of...
Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
• 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt,...
Pfizer’s Newest RA Survey Finds a Disconnect in Doctor-Patient Communication
Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management....
Novartis Foundation and partners launch of the of the Ho Chi Minh City Communities for Healthy Hearts Program in Vietnam
• Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...